KAN Research Institute

KAN Research Institute is a specialized drug discovery subsidiary of Eisai Co., Ltd., located in the Kobe Biomedical Innovation Cluster in Japan. The institute focuses on identifying novel therapeutic targets and developing first-in-class drug candidates through its proprietary Integrative Cell Biology platform. Their research is primarily centered on immunology, oncology, and neurobiology, with a focus on refractory diseases. KAN Research Institute is most notable for discovering E6011, a first-in-class anti-fractalkine (CX3CL1) monoclonal antibody currently in clinical development. The organization functions as a creative research hub within the Eisai group, bridging basic science with clinical application.